Open AccessSuccessful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children’s Oncology Group AALL0434
Author(s) -
Robert J. Hayashi,
Stuart S. Winter,
Kimberly P. Dunsmore,
Meenakshi Devidas,
Zhiguo Chen,
Brent L. Wood,
Michelle L. Hermiston,
David T. Teachey,
Sherrie L. Perkins,
Rodney R. Miles,
Elizabeth A. Raetz,
Mig L. Loh,
Naomi J. Winick,
William L. Carroll,
Stephen P. Hunger,
Megan S. Lim,
Thomas G. Gross,
Catherine M. Bollard
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.20.00531
Subject(s) - medicine , regimen , lymphoblastic lymphoma , methotrexate , induction chemotherapy , lymphoma , surgery , oncology , chemotherapy , immunology , t cell , immune system
The Children's Oncology Group (COG) protocol AALL0434 evaluated the safety and efficacy of multi-agent chemotherapy with Capizzi-based methotrexate/pegaspargase (C-MTX) in patients with newly diagnosed pediatric T-cell lymphoblastic lymphoma (T-LL) and gained preliminary data using nelarabine in high-risk patients.